The cohort of companies developing products for treating cancer with genetically engineered T-cells has increased with the announcement that Merck Serono and Intrexon Corp will collaborate to generate new drug candidates using the technology. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News Regenerative Medicine
